Jazz Pharmaceuticals Announces First Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Jazz Pharmaceuticals (JAZZ) PT Raised to $201 at BMO Capital
May 9, 2018 6:45 AM EDTBMO Capital raised its price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $201.00 (from $199.00) while maintaining an Outperform rating.
Analyst Gary Nachman commented, "JAZZ reported 1Q revenue of $445mm vs. BMO/consensus $433mm/$434mm and adj. EPS of $2.98 vs. BMO/consensus $2.74/$2.77. The... More
Jazz Pharmaceuticals (JAZZ) Tops Q1 EPS by 21c
May 8, 2018 4:34 PM EDTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 EPS of $2.98, $0.21 better than the analyst estimate of $2.77. Revenue for the quarter came in at $444.61 million versus the consensus estimate of $434.87 million.
"The first quarter was highlighted by strong revenue growth, cash flow generation and execution across... More
